** Shares of drugmaker Rigel Pharmaceuticals RIGL.O rise ~3% to $19.54
** RIGL says it has settled patent litigation with Annora Pharma regarding co's blood disorder drug, Tavalisse, to treat patients with immune thrombocytopenia $(ITP)$ who haven't responded adequately to prior treatments
** Lawsuit began when Annora submitted an application to the FDA to market a generic version of Tavalisse
** ITP is a condition where the immune system mistakenly attacks and destroys platelets, leading to a low platelet count and increased risk of bleeding
** Under the settlement, Annora will be allowed to sell its generic version starting in Q2 2032 or earlier under certain circumstances
** Annora did not immediately respond to Reuters' request for comment
** RIGL gained 33.6% in the last 12 months
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。